Purinostat mesylate is a selective HDAC inhibitor with IC50 values ranging from 0.81 to 11.5 nM against class I and IIb HDACs; it induces apoptosis in LAMA84 and 188BL-2 cells, affects the cell cycle, exhibits potent anti-leukemic activity in vivo, and can be used in the research of lymphocytic leukemia.